Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joseph Haas

Senior Writer

Washington, DC

Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.

Latest From Joseph Haas

Ultragenyx Data De-Risk Phase III Trial Of Setrusumab

The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.

Clinical Trials Drug Approval Standards

Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry

Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?

Business Strategies Clinical Trials

Oculis Looks To Move Dry Eye Candidate To Phase III Despite Mixed Dataset

Oculis’s licaminlimab showed ability to treat a sign of dry eye disease in a genetic subpopulation, but data in the fuller Phase IIb trial enrollment were less impressive.

Clinical Trials Business Strategies

Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid

Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.

Deal Watch Business Strategies

Biomea’s Novel Diabetes Candidate Placed On FDA Hold

Biomea reported that the FDA placed a clinical hold on two ongoing Phase I/II diabetes studies of menin inhibitor BMF-219 due to concerns about liver toxicity.

Clinical Trials Business Strategies

Amgen Phase III Data Could Add Second Indication To Uplizna’s Label

Amgen’s study shows an 87% risk-reduction for IgG4-related disease flares, which can exacerbate the rare disorder and lead to irreversible organ failure. A US filing is planned.

Clinical Trials Rare Diseases
See All
UsernamePublicRestriction

Register